Trial Profile
Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD3/MUC1-armed cytokine induced killer cells-Benhealth Biopharmaceutical (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Oct 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 13 Oct 2020 Planned End Date changed from 25 Mar 2021 to 25 Aug 2020.
- 10 Sep 2019 Planned primary completion date changed from 25 Mar 2019 to 25 Mar 2020.